138 related articles for article (PubMed ID: 26123383)
21. Pretherapeutic evaluation of patients with upper gastrointestinal tract cancer using endoscopic and laparoscopic ultrasonography.
Mortensen MB
Dan Med J; 2012 Dec; 59(12):B4568. PubMed ID: 23290296
[TBL] [Abstract][Full Text] [Related]
22. Pancreatic adenocarcinoma: number of positive nodes allows to distinguish several N categories.
Strobel O; Hinz U; Gluth A; Hank T; Hackert T; Bergmann F; Werner J; Büchler MW
Ann Surg; 2015 May; 261(5):961-9. PubMed ID: 24979603
[TBL] [Abstract][Full Text] [Related]
23. A prolonged follow-up provides new insights into locally advanced pancreatic cancer treatment.
Goéré D; Patriti A; Deutsch E; Elias D; Ducreux M
Gastroenterol Clin Biol; 2008; 32(6-7):649-52. PubMed ID: 18487030
[TBL] [Abstract][Full Text] [Related]
24. Chemoradiation for resected pancreatic adenocarcinoma with or without intraoperative radiation therapy boost: Long-term outcomes.
Calvo FA; Sole CV; Atahualpa F; Lozano MA; Gomez-Espi M; Calin A; García-Alfonso P; Gonzalez-Bayon L; Herranz R; García-Sabrido JL
Pancreatology; 2013; 13(6):576-82. PubMed ID: 24280572
[TBL] [Abstract][Full Text] [Related]
25. Splenic artery invasion in pancreatic adenocarcinoma of the body and tail: a novel prognostic parameter for patient selection.
Partelli S; Crippa S; Barugola G; Tamburrino D; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
Ann Surg Oncol; 2011 Dec; 18(13):3608-14. PubMed ID: 21584836
[TBL] [Abstract][Full Text] [Related]
26. Pancreatic neoplasm in 2011: an update.
Saif MW
JOP; 2011 Jul; 12(4):316-21. PubMed ID: 21737886
[TBL] [Abstract][Full Text] [Related]
27. Impact of histological response after neoadjuvant chemoradiotherapy on recurrence-free survival in UICC-T3 pancreatic adenocarcinoma but not in UICC-T4.
Murata Y; Mizuno S; Kishiwada M; Hamada T; Usui M; Sakurai H; Tabata M; Inoue H; Shiraishi T; Isaji S
Pancreas; 2012 Jan; 41(1):130-6. PubMed ID: 21934551
[TBL] [Abstract][Full Text] [Related]
28. [Pancreatectomy for adenocarcinoma: prognostic factors, recommendations for pathological reports].
Chatelain D; Fléjou JF
Ann Pathol; 2002 Oct; 22(5):422-31. PubMed ID: 12483163
[TBL] [Abstract][Full Text] [Related]
29. Pancreatic hepatoid carcinoma: a review of the literature.
Marchegiani G; Gareer H; Parisi A; Capelli P; Bassi C; Salvia R
Dig Surg; 2013; 30(4-6):425-33. PubMed ID: 24281319
[TBL] [Abstract][Full Text] [Related]
30. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer.
Kondo N; Murakami Y; Uemura K; Hayashidani Y; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Shigemoto N; Kato Y; Ohge H; Sueda T
Ann Surg Oncol; 2010 Sep; 17(9):2321-9. PubMed ID: 20336387
[TBL] [Abstract][Full Text] [Related]
31. Single-Institution Experience with Irreversible Electroporation for T4 Pancreatic Cancer: First 50 Patients.
Kluger MD; Epelboym I; Schrope BA; Mahendraraj K; Hecht EM; Susman J; Weintraub JL; Chabot JA
Ann Surg Oncol; 2016 May; 23(5):1736-43. PubMed ID: 26714959
[TBL] [Abstract][Full Text] [Related]
32. [Management of localized, locally advanced and metastatic pancreatic adenocarcinoma].
Delpero JR; Turrini O; Raoul JL
Rev Prat; 2015 Mar; 65(3):382-9. PubMed ID: 26016202
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization.
Panzuto F; Nasoni S; Falconi M; Corleto VD; Capurso G; Cassetta S; Di Fonzo M; Tornatore V; Milione M; Angeletti S; Cattaruzza MS; Ziparo V; Bordi C; Pederzoli P; Delle Fave G
Endocr Relat Cancer; 2005 Dec; 12(4):1083-92. PubMed ID: 16322345
[TBL] [Abstract][Full Text] [Related]
34. Advancements in pancreatic neuroendocrine tumors.
Sadaria MR; Hruban RH; Edil BH
Expert Rev Gastroenterol Hepatol; 2013 Jul; 7(5):477-90. PubMed ID: 23899286
[TBL] [Abstract][Full Text] [Related]
35. Can Neoadjuvant Therapy in Pancreatic Cancer Increase the Pool of Patients Eligible for Pancreaticoduodenectomy?
Hackert T; Ulrich A; Büchler MW
Adv Surg; 2017 Sep; 51(1):1-10. PubMed ID: 28797331
[No Abstract] [Full Text] [Related]
36. The impact of metastatic sites in advanced pancreatic adenocarcinoma, systematic review and meta-analysis of prospective randomized studies.
Usón PLS; Tolentino FDS; Santos VM; Rother ET; Maluf FC
PLoS One; 2020; 15(3):e0230060. PubMed ID: 32130264
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant therapy is associated with a reduced lymph node ratio in patients with potentially resectable pancreatic cancer.
Roland CL; Yang AD; Katz MH; Chatterjee D; Wang H; Lin H; Vauthey JN; Pisters PW; Varadhachary GR; Wolff RA; Crane CH; Lee JE; Fleming JB
Ann Surg Oncol; 2015 Apr; 22(4):1168-75. PubMed ID: 25352267
[TBL] [Abstract][Full Text] [Related]
38. The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma.
Abbott DE; Tzeng CW; Merkow RP; Cantor SB; Chang GJ; Katz MH; Bentrem DJ; Bilimoria KY; Crane CH; Varadhachary GR; Abbruzzese JL; Wolff RA; Lee JE; Evans DB; Fleming JB
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S500-8. PubMed ID: 23397153
[TBL] [Abstract][Full Text] [Related]
39. Rare long-term survivors of pancreatic adenocarcinoma without curative resection.
Oh SY; Edwards A; Mandelson MT; Lin B; Dorer R; Helton WS; Kozarek RA; Picozzi VJ
World J Gastroenterol; 2015 Dec; 21(48):13574-81. PubMed ID: 26730170
[TBL] [Abstract][Full Text] [Related]
40. Systematic review of the clinical significance of lymph node micrometastases of pancreatic adenocarcinoma following surgical resection.
Choi SB; Han HJ; Park P; Kim WB; Song TJ; Choi SY
Pancreatology; 2017; 17(3):342-349. PubMed ID: 28336226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
